Reading the tea leaves: Anticarcinogenic properties of (-)- epigallocatechin-3-gallate

Jennifer R. Carlson, Brent A Bauer, Ann Vincent, Paul John Limburg, Ted Wilson

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Green tea is an extremely popular beverage worldwide. Derivatives of green tea, particularly (-)epigallocatechin-3-gallate (EGCG), have been proposed to have anticarcinogenic properties based on preclinical, observational, and clinical trial data. To summarize, clarify, and extend current knowledge, we conducted a comprehensive search of the PubMed database and other secondary data sources, as appropriate, regarding the chemopreventive potential of EGCG. Apparently, EGCG functions as an antioxidant, preventing oxidative damage in healthy cells, but also as an antiangiogenic agent, preventing tumors from developing a blood supply needed to grow larger. Furthermore, EGCG may stimulate apoptosis in cancerous cells by negatively regulating the cell cycle to prevent continued division. Finally, EGCG exhibits antibacterial activity, which may be implicated in the prevention of gastric cancer. Although in vitro research of the anticarcinogenic properties of EGCG seems promising, many diverse and unknown factors may influence its in vivo activity in animal and human models. Some epidemiological studies suggest that green tea compounds could protect against cancer, but existing data are inconsistent, and limitations in study design hinder full interpretation and generalizability of the published observational findings. Several clinical trials with green tea derivatives are ongoing, and further research should help to clarify the clinical potential of EGCG for chemoprevention and/or chemotherapy applications.

Original languageEnglish (US)
Pages (from-to)725-732
Number of pages8
JournalMayo Clinic Proceedings
Volume82
Issue number6
DOIs
StatePublished - 2007

Fingerprint

Tea
Reading
Clinical Trials
Angiogenesis Inhibitors
Information Storage and Retrieval
Beverages
Chemoprevention
epigallocatechin gallate
Research
PubMed
Stomach Neoplasms
Epidemiologic Studies
Neoplasms
Cell Cycle
Animal Models
Antioxidants
Databases
Apoptosis
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Reading the tea leaves : Anticarcinogenic properties of (-)- epigallocatechin-3-gallate. / Carlson, Jennifer R.; Bauer, Brent A; Vincent, Ann; Limburg, Paul John; Wilson, Ted.

In: Mayo Clinic Proceedings, Vol. 82, No. 6, 2007, p. 725-732.

Research output: Contribution to journalArticle

@article{66f0d341afeb47a1b98cf3c417a64869,
title = "Reading the tea leaves: Anticarcinogenic properties of (-)- epigallocatechin-3-gallate",
abstract = "Green tea is an extremely popular beverage worldwide. Derivatives of green tea, particularly (-)epigallocatechin-3-gallate (EGCG), have been proposed to have anticarcinogenic properties based on preclinical, observational, and clinical trial data. To summarize, clarify, and extend current knowledge, we conducted a comprehensive search of the PubMed database and other secondary data sources, as appropriate, regarding the chemopreventive potential of EGCG. Apparently, EGCG functions as an antioxidant, preventing oxidative damage in healthy cells, but also as an antiangiogenic agent, preventing tumors from developing a blood supply needed to grow larger. Furthermore, EGCG may stimulate apoptosis in cancerous cells by negatively regulating the cell cycle to prevent continued division. Finally, EGCG exhibits antibacterial activity, which may be implicated in the prevention of gastric cancer. Although in vitro research of the anticarcinogenic properties of EGCG seems promising, many diverse and unknown factors may influence its in vivo activity in animal and human models. Some epidemiological studies suggest that green tea compounds could protect against cancer, but existing data are inconsistent, and limitations in study design hinder full interpretation and generalizability of the published observational findings. Several clinical trials with green tea derivatives are ongoing, and further research should help to clarify the clinical potential of EGCG for chemoprevention and/or chemotherapy applications.",
author = "Carlson, {Jennifer R.} and Bauer, {Brent A} and Ann Vincent and Limburg, {Paul John} and Ted Wilson",
year = "2007",
doi = "10.4065/82.6.725",
language = "English (US)",
volume = "82",
pages = "725--732",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "6",

}

TY - JOUR

T1 - Reading the tea leaves

T2 - Anticarcinogenic properties of (-)- epigallocatechin-3-gallate

AU - Carlson, Jennifer R.

AU - Bauer, Brent A

AU - Vincent, Ann

AU - Limburg, Paul John

AU - Wilson, Ted

PY - 2007

Y1 - 2007

N2 - Green tea is an extremely popular beverage worldwide. Derivatives of green tea, particularly (-)epigallocatechin-3-gallate (EGCG), have been proposed to have anticarcinogenic properties based on preclinical, observational, and clinical trial data. To summarize, clarify, and extend current knowledge, we conducted a comprehensive search of the PubMed database and other secondary data sources, as appropriate, regarding the chemopreventive potential of EGCG. Apparently, EGCG functions as an antioxidant, preventing oxidative damage in healthy cells, but also as an antiangiogenic agent, preventing tumors from developing a blood supply needed to grow larger. Furthermore, EGCG may stimulate apoptosis in cancerous cells by negatively regulating the cell cycle to prevent continued division. Finally, EGCG exhibits antibacterial activity, which may be implicated in the prevention of gastric cancer. Although in vitro research of the anticarcinogenic properties of EGCG seems promising, many diverse and unknown factors may influence its in vivo activity in animal and human models. Some epidemiological studies suggest that green tea compounds could protect against cancer, but existing data are inconsistent, and limitations in study design hinder full interpretation and generalizability of the published observational findings. Several clinical trials with green tea derivatives are ongoing, and further research should help to clarify the clinical potential of EGCG for chemoprevention and/or chemotherapy applications.

AB - Green tea is an extremely popular beverage worldwide. Derivatives of green tea, particularly (-)epigallocatechin-3-gallate (EGCG), have been proposed to have anticarcinogenic properties based on preclinical, observational, and clinical trial data. To summarize, clarify, and extend current knowledge, we conducted a comprehensive search of the PubMed database and other secondary data sources, as appropriate, regarding the chemopreventive potential of EGCG. Apparently, EGCG functions as an antioxidant, preventing oxidative damage in healthy cells, but also as an antiangiogenic agent, preventing tumors from developing a blood supply needed to grow larger. Furthermore, EGCG may stimulate apoptosis in cancerous cells by negatively regulating the cell cycle to prevent continued division. Finally, EGCG exhibits antibacterial activity, which may be implicated in the prevention of gastric cancer. Although in vitro research of the anticarcinogenic properties of EGCG seems promising, many diverse and unknown factors may influence its in vivo activity in animal and human models. Some epidemiological studies suggest that green tea compounds could protect against cancer, but existing data are inconsistent, and limitations in study design hinder full interpretation and generalizability of the published observational findings. Several clinical trials with green tea derivatives are ongoing, and further research should help to clarify the clinical potential of EGCG for chemoprevention and/or chemotherapy applications.

UR - http://www.scopus.com/inward/record.url?scp=34249947773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249947773&partnerID=8YFLogxK

U2 - 10.4065/82.6.725

DO - 10.4065/82.6.725

M3 - Article

C2 - 17550753

AN - SCOPUS:34249947773

VL - 82

SP - 725

EP - 732

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 6

ER -